Pipeline Resurrection: An Interview With Interleukin Genetics CEO Lewis Bender (Part 1)
This article was originally published in The Pink Sheet Daily
Executive Summary
Diagnostic technology could revive countless abandoned projects in Big Pharma R&D pipelines. But making that happen is harder than you think.